Want to see IN:INDOUS full AI Analyst Report?
Top Page
Indo US Bio-Tech Ltd.
(INDOUS)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹83.00
▼(-23.15% Downside)
Action:Reiterated
Date:09/10/26
The score is held back mainly by weak cash conversion (negative operating and free cash flow) alongside rising debt, despite strong reported revenue growth and a generally acceptable equity base. Technicals are also a headwind with the stock trading below major moving averages and a negative MACD, while valuation is moderately supportive with a mid-range P/E.
Positive Factors
Strong Revenue Growth
The sharp FY2026 revenue increase indicates strong demand conversion across the company’s seed business and expanding commercial reach. If the growth is sustained, it can support greater operating scale, strengthen distributor relationships, and provide a broader base for future earnings.
Negative Factors
Weak Cash Conversion
Negative operating and free cash flow show that reported business activity did not translate into cash during FY2026. Persistent weak conversion can restrict internally funded growth, increase reliance on external financing, and reduce flexibility when seasonal working-capital needs arise.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp FY2026 revenue increase indicates strong demand conversion across the company’s seed business and expanding commercial reach. If the growth is sustained, it can support greater operating scale, strengthen distributor relationships, and provide a broader base for future earnings.
Read all positive factors
Indo US Bio-Tech Ltd. (INDOUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.61B
Dividend Yield0.08%
Average Volume (3M)1.14K
Price to Earnings (P/E)14.0
Beta (1Y)1.02
Revenue Growth2.52%
EPS Growth-35.64%
CountryIN
Employees883
SectorGeneral
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)3.56
Shares Outstanding20,052,000
10 Day Avg. Volume852
30 Day Avg. Volume1,143
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.24
Price to Sales (P/S)1.87
P/FCF Ratio-13.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Indo US Bio-Tech Ltd. Business Overview & Revenue Model
Company Description
Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, in...
How the Company Makes Money
Indo US Bio-Tech Ltd. primarily makes money by selling agricultural seeds to distributors/dealers and, directly or indirectly, to farmers. Revenue is generally generated from (1) sales of hybrid/varietal seeds across crop categories (e.g., field c...
Indo US Bio-Tech Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 642.31M | 1.10B | 1.04B |
| Gross Profit | 143.60M | 301.69M | 294.70M |
| EBITDA | 88.39M | 170.66M | 2.23M |
| Net Income | 71.37M | 131.23M | 162.67M |
Balance Sheet | |||
| Total Assets | 1.17B | 1.33B | 978.43M |
| Cash, Cash Equivalents and Short-Term Investments | 5.88M | 69.13M | 2.48M |
| Total Debt | 276.43M | 370.36M | 148.36M |
| Total Liabilities | 305.44M | 405.63M | 193.24M |
| Stockholders Equity | 866.69M | 925.34M | 785.18M |
Cash Flow | |||
| Free Cash Flow | -83.36M | -149.89M | -100.69K |
| Operating Cash Flow | -74.56M | -125.81M | 91.00 |
| Investing Cash Flow | -34.90M | -15.00M | -7.92M |
| Financing Cash Flow | 104.92M | 199.56M | -14.77M |
Indo US Bio-Tech Ltd. Technical Analysis
Negative
108.00
Price Trends
83.78
Negative
91.42
Negative
106.13
Negative
Market Momentum
-1.28
Positive
46.47
Neutral
46.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDOUS, the sentiment is Negative. The current price of 108 is above the 20-day moving average (MA) of 81.91, above the 50-day MA of 83.78, and above the 200-day MA of 106.13, indicating a bearish trend. The MACD of -1.28 indicates Positive momentum. The RSI at 46.47 is Neutral, neither overbought nor oversold. The STOCH value of 46.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDOUS.
Indo US Bio-Tech Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹4.60B | 11.04 | ― | ― | ― | ― | |
61 Neutral | ₹2.85B | 8.28 | ― | 1.31% | 21.02% | -3.13% | |
56 Neutral | ₹6.90B | 22.79 | ― | 1.04% | -24.14% | -56.81% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.61B | 13.95 | ― | 0.08% | 2.52% | -35.64% | |
55 Neutral | ₹15.63B | 14.53 | ― | 0.55% | 17.05% | 9.10% | |
49 Neutral | ₹17.00B | -23.65 | ― | 0.12% | 9.33% | 53.30% |
* General Sector Average
IN:INDOUS
Indo US Bio-Tech Ltd.
77.74
-71.51
-47.91%
IN:ASTEC
Astec Lifesciences Limited
711.85
-142.65
-16.69%
IN:BESTAGRO
Best Agrolife Ltd.
19.16
-6.12
-24.21%
IN:IPL
India Pesticides Ltd.
135.65
-75.01
-35.61%
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
149.65
-19.30
-11.42%
IN:IGCL
Indogulf Cropsciences Limited
72.10
-39.45
-35.37%
Indo US Bio-Tech Ltd. Corporate Events
Indo US Bio-Tech Sets Virtual Date for 22nd Annual General Meeting
Sep 6, 2026
Indo US Bio-Tech Ltd. has announced that its 22nd Annual General Meeting will be held on September 30, 2026 at 2:30 p.m. via video conferencing and other audio-visual means, in line with recent circulars issued by the Ministry of Corporate Affairs...
Indo Us Bio-Tech Completes Postal Ballot Dispatch and Opens Remote E-Voting
Jul 5, 2026
Indo Us Bio-Tech Limited has completed dispatch of its postal ballot notice dated July 4, 2026 to shareholders whose names appeared on the register as of June 26, 2026, and has published the required advertisement in English and Gujarati editions ...
Indo US Bio-Tech Closes Trading Window Ahead of Quarterly Results
Jun 29, 2026
Indo US Bio-Tech Ltd. has announced that its trading window for dealing in company securities will be closed from July 1, 2026, in line with its code of conduct and the SEBI Prohibition of Insider Trading Regulations. The window will reopen 48 hou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.